- Home
- MASI vs LEGN Comparison
MASI vs LEGN Comparison
Compare MASI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MASI | LEGN |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MASI | LEGN |
|---|---|---|
| Price | $175.50 | $19.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $184.25 | $63.46 |
| AVG Volume (30 Days) | ★ 2.3M | 2.0M |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.05 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,239,153,000.00 | N/A |
| Revenue This Year | $8.59 | $67.56 |
| Revenue Next Year | $7.60 | $43.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.34 | N/A |
| 52 Week Low | $125.94 | $16.24 |
| 52 Week High | $175.90 | $45.30 |
Technical Indicators
Market Signals| Indicator | MASI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 75.53 | 52.59 |
| Support Level | $157.54 | $16.24 |
| Resistance Level | $175.90 | $23.68 |
| Average True Range (ATR) | 0.49 | 0.86 |
| MACD | -0.14 | 0.15 |
| Stochastic Oscillator | 66.67 | 41.02 |
Price Performance
Historical ComparisonAbout MASI Masimo Corporation
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.